Has trastuzumab been approved in China?

Fam-trastuzumab deruxtecan-nxki has been approved in China. This is an antibody-drug conjugate that provides a new treatment option for many patients with HER2-positive or low-expression breast cancer. The research and development of trastuzumab is jointly conducted by AstraZeneca and Daiichi Sankyo, and has achieved remarkable research results worldwide.

What makes trastuzumab unique is its precise therapeutic mechanism. By binding to the HER2 receptor on the surface of tumor cells, it accurately delivers cytotoxic drugs to the tumor site to achieve a more efficient and specific killing effect. This characteristic allows trastuzumab to significantly extend the survival of patients and reduce the risk of disease progression compared with traditional drugs when treating HER2-positive breast cancer.

The National Medical Products Administration's approval of trastuzumab was based on its excellent performance in a series of clinical trials. Especially in a trial called DESTINY-Breast03, compared with trastuzumab, trastuzumab reduced patients' risk of disease progression or death by 72%. This result undoubtedly brings new hope to breast cancer patients.

The safety of trastuzumab has also been verified in clinical trials. Although some adverse reactions may occur during use, generally speaking, these reactions are controllable, and compared with traditional chemotherapy drugs, trastuzumab has fewer side effects and the patient's quality of life has been significantly improved. Therefore, the approval of trastuzumab provides a new, efficient and relatively safe treatment option for Chinese patients with HER2-positive or low-expression breast cancer.